• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Pyott reappointed

Article

The board of directors of Allergan has reappointed David E.I. Pyott as president, effective March 27. Pyott? who previously served as president from 1998 until 2006 ? also will continue to serve Allergan in his current roles as chairman of the board and chief executive officer. Pyott's role as president is not an interim position, and Allergan does not plan to name a new president.

Irvine, CA-The board of directors of Allergan has reappointed David E.I. Pyott as president, effective March 27.

Pyott-who previously served as president from 1998 until 2006-also will continue to serve Allergan in his current roles as chairman of the board and chief executive officer (CEO). Pyott’s role as president is not an interim position, and Allergan does not plan to name a new president.

Pyott succeeds F. Michael Ball, who has accepted the position of CEO of Hospira, a specialty pharmaceutical and medication delivery company based in Lake Forest, IL.

According to Allergan, Pyott expanding his role as president will allow for a seamless management transition and continuity in execution of Allergan’s established strategies. It also will allow Pyott to invest more of his efforts in the development of the strong bench of Allergan leaders and their teams.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.